Skip to content
value.today

Pharmaceutics International, Inc.

Total raised
$201 M
16 rounds on record
Latest round
$11 M
Jun 2024
First round on record
Aug 2016
Today
Acquired
Acquired by Jabil Inc.

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of Pharmaceutics International, Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
Pharmaceutics International, IncJabil Inc.2025—$309 M—Annual report

Funding rounds

16 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pharmaceutics International, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2024$11 MNo. 16$10 to $50 million

Pharmaceutics International, Inc.: Raise no. 16, Jun 2024

Investors in this round

3 investors had bought by the notice of Oct 23, 2024: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John E Fowler · Executive Officer, Director
  • David E Solomon · Director
  • James E Gale · Director
  • Mark E Kavulich · Director
  • Michael E Bogda · Director
  • Syed E Abidi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gerard Fleury, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 23, 2024. Read the notice at the SEC.

equitySEC
Mar 2024$4 MNo. 15$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 15, Mar 2024

Investors in this round

6 investors had bought by the notice of Mar 13, 2024: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John E. Fowler · Executive Officer, Director
  • Joseph E. Kiely · Executive Officer
  • David E. Solomon · Director
  • James E. Gale · Director
  • Mark E. Kavulich · Director
  • Michael E. Bogda · Director
  • Syed E. Abidi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph Kiely, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 13, 2024. Read the notice at the SEC.

equitySEC
Jun 2023$6 MNo. 14$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 14, Jun 2023

Investors in this round

2 investors had bought by the notice of Jun 27, 2023: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $12 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John E. Fowler · Executive Officer, Director
  • Joseph E. Kiely · Executive Officer
  • David E. Solomon · Director
  • James E. Gale · Director
  • Mark E. Kavulich · Director
  • Michael E. Bogda · Director
  • Syed E. Abidi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph Kiely, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 27, 2023. Read the notice at the SEC.

equitySEC
Dec 2022$3 MNo. 13$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 13, Dec 2022

Investors in this round

5 investors had bought by the notice of Dec 12, 2022: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John E. Fowler · Executive Officer, Director
  • Joseph E. Kiely · Executive Officer
  • David E. Solomon · Director
  • James E. Gale · Director
  • Mark E. Kavulich · Director
  • Michael E. Bogda · Director
  • Syed E. Abidi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph Kiely, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 12, 2022. Read the notice at the SEC.

equitySEC
Sep 2022$9 MNo. 12$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 12, Sep 2022

Investors in this round

5 investors had bought by the notice of Oct 7, 2022: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John E. Fowler · Executive Officer, Director
  • John E. Guthrie · Executive Officer
  • David E. Solomon · Director
  • James E. Gale · Director
  • Michael I. Bogda · Director
  • Sana I. Abidi · Director
  • Syed E. Abidi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Guthrie, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 7, 2022. Read the notice at the SEC.

equitySEC
Aug 2022$5 MNo. 11$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 11, Aug 2022

Investors in this round

5 investors had bought by the notice of Aug 22, 2022: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John I. Fowler · Executive Officer, Director
  • John I. Guthrie · Executive Officer
  • David E. Solomon · Director
  • James E. Gale · Director
  • Michael N. Bogda · Director
  • Shahab N. Abidi · Director
  • Syed E. Abidi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Guthrie, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 22, 2022. Read the notice at the SEC.

equitySEC
Jun 2022$5 MNo. 10$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 10, Jun 2022

Investors in this round

5 investors had bought by the notice of Jul 12, 2022: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John I. Fowler · Executive Officer, Director
  • John I. Guthrie · Executive Officer
  • David I. Solomon · Director
  • James I. Gale · Director
  • Michael I. Bogda · Director
  • Shahab N. Abidi · Director
  • Syed E. Abidi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Guthrie, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 12, 2022. Read the notice at the SEC.

equitySEC
Mar 2022$5 MNo. 9$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 9, Mar 2022

Investors in this round

4 investors had bought by the notice of Mar 17, 2022: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John E. Fowler · Executive Officer, Director
  • John E. Guthrie · Executive Officer
  • David E. Solomon · Director
  • James E. Gale · Director
  • Michael E. Bogda · Director
  • Sana E. Abidi · Director
  • Syed E. Abidi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Guthrie, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 17, 2022. Read the notice at the SEC.

equitySEC
Dec 2021$5 MNo. 8$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 8, Dec 2021

Investors in this round

2 investors had bought by the notice of Jan 11, 2022: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John E. Guthrie · Executive Officer
  • Kurt E. Nielsen, Ph.D. · Executive Officer, Director
  • David E. Solomon · Director
  • James E. Gale · Director
  • Michael E. Bogda · Director
  • Sana E. Abidi · Director
  • Syed E. Abidi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Guthrie, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 11, 2022. Read the notice at the SEC.

equitySEC
Oct 2021$5 MNo. 7$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 7, Oct 2021

Investors in this round

2 investors had bought by the notice of Oct 29, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John E. Guthrie · Executive Officer
  • Kurt E. Nielsen, Ph.D. · Executive Officer, Director
  • David E. Solomon · Director
  • George E. Svokos · Director
  • James E. Gale · Director
  • Michael E. Bogda · Director
  • Sana E. Abidi · Director
  • Syed E. Abidi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Guthrie, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 29, 2021. Read the notice at the SEC.

equitySEC
Jul 2021$6 MNo. 6$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 6, Jul 2021

Investors in this round

5 investors had bought by the notice of Aug 6, 2021: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John I. Guthrie · Executive Officer
  • Kurt I. Nielsen, Ph.D. · Executive Officer, Director
  • David I. Solomon · Director
  • George I. Svokos · Director
  • James I. Gale · Director
  • Michael I. Bogda · Director
  • Sana I. Abidi · Director
  • Syed E. Abidi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Guthrie, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 6, 2021. Read the notice at the SEC.

equitySEC
May 2021$3 MNo. 5$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 5, May 2021

Investors in this round

4 investors had bought by the notice of Jun 4, 2021: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John I. Guthrie · Executive Officer
  • Kurt I. Nielsen, Ph.D. · Executive Officer
  • David I. Solomon · Director
  • James I. Gale · Director
  • Michael I. Bogda · Director
  • Sana I. Abidi · Director
  • Syed E. Abidi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Guthrie, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 4, 2021. Read the notice at the SEC.

equitySEC
Dec 2020$10 MNo. 4$10 to $50 million

Pharmaceutics International, Inc.: Raise no. 4, Dec 2020

Investors in this round

6 investors had bought by the notice of Jun 4, 2021: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John I. Guthrie · Executive Officer
  • Kurt I. Nielsen, Ph.D. · Executive Officer
  • David I. Solomon · Director
  • James I. Gale · Director
  • Michael I. Bogda · Director
  • Sana I. Abidi · Director
  • Syed E. Abidi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Guthrie, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 4, 2021. Read the notice at the SEC.

equitySEC
Oct 2018$6 MNo. 3$2 to $10 million

Pharmaceutics International, Inc.: Raise no. 3, Oct 2018

Investors in this round

5 investors had bought by the notice of Oct 29, 2018: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $15 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John I. Guthrie · Executive Officer
  • Michael E. Bogda · Executive Officer, Director
  • Syed E. Abidi, Ph.D. · Executive Officer, Director
  • David E. Solomon · Director
  • James E. Gale · Director
  • Kevin I. Walsh · Director
  • Sana I. Abidi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The amounts reflected above have been rounded to the closest whole number.”

Signed by Syed E. Abidi, Ph.D., Chairman and CEO. Source: SEC Form D, newest notice filed Oct 29, 2018. Read the notice at the SEC.

equitySEC
Aug 2017$10 MNo. 2$10 to $50 million

Pharmaceutics International, Inc.: Raise no. 2, Aug 2017

Investors in this round

6 investors had bought by the notice of Aug 15, 2017: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $20 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gerard I. Fleury · Executive Officer
  • Julien E. Hecht · Executive Officer
  • Michael E. Bogda · Executive Officer, Director
  • Syed E. Abidi, Ph.D. · Executive Officer, Director
  • David E. Solomon · Director
  • James E. Gale · Director
  • Sana I. Abidi · Director
  • Shahid I. Raza · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Bogda, President. Source: SEC Form D, newest notice filed Aug 15, 2017. Read the notice at the SEC.

equitySEC
Aug 2016$108 MNo. 1$50 to $250 million

Pharmaceutics International, Inc.: Raise no. 1, Aug 2016

Investors in this round

9 investors had bought by the notice of Sep 14, 2016: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$108 M of $108 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$2,574,282
Paid to its own people
$9,695,085 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jillian E. Dettinger · Executive Officer
  • Julien E. Hecht · Executive Officer
  • Michael E. Bogda · Executive Officer, Director
  • Syed E. Abidi · Executive Officer, Director
  • David E. Solomon · Director
  • James E. Gale · Director
  • Sana I. Abidi · Director
  • Shahid I. Raza · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Teneo Securities LLC (CRD 151256) · New York, New YorkSold in NY

Remarks in the notice

  • On the amounts: “Total amount sold reflects proceeds consisting of cash and real estate.”

Signed by Michael Bogda, President. Source: SEC Form D, newest notice filed Sep 14, 2016. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pharmaceutics International, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2024).

    SEC Form D · Oct 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2024

That is all the official record says: Pharmaceutics International, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Pharmaceutics International, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 16 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pharmaceutics International, Inc.
NameRoleNamed in
John E FowlerExecutive officerOct 2024
Joseph E KielyExecutive officerJun 2024
John E. FowlerExecutive officerMar 2024
Joseph E. KielyExecutive officerMar 2024
John E. GuthrieExecutive officerOct 2022
John I. FowlerExecutive officerAug 2022
John I. GuthrieExecutive officerAug 2022
Kurt E. Nielsen, Ph.D.Executive officerJan 2022
Kurt I. Nielsen, Ph.D.Executive officerAug 2021
Michael E. BogdaExecutive officerOct 2018
Syed E. Abidi, Ph.D.Executive officerOct 2018
Gerard I. FleuryExecutive officerAug 2017
Julien E. HechtExecutive officerAug 2017
Jillian E. DettingerExecutive officerSep 2016
Syed E. AbidiExecutive officerSep 2016
David E SolomonDirectorOct 2024
James E GaleDirectorOct 2024
John E FowlerDirectorOct 2024
Mark E KavulichDirectorOct 2024
Michael E BogdaDirectorOct 2024
Syed E Abidi, Ph.D.DirectorOct 2024
David E. SolomonDirectorMar 2024
James E. GaleDirectorMar 2024
John E. FowlerDirectorMar 2024
Mark E. KavulichDirectorMar 2024
Michael E. BogdaDirectorMar 2024
Syed E. Abidi, Ph.D.DirectorMar 2024
Michael I. BogdaDirectorOct 2022
Sana I. AbidiDirectorOct 2022
John I. FowlerDirectorAug 2022
Michael N. BogdaDirectorAug 2022
Shahab N. AbidiDirectorAug 2022
David I. SolomonDirectorJul 2022
James I. GaleDirectorJul 2022
Syed E. AbidiDirectorJul 2022
Sana E. AbidiDirectorMar 2022
Kurt E. Nielsen, Ph.D.DirectorJan 2022
George E. SvokosDirectorOct 2021
George I. SvokosDirectorAug 2021
Kurt I. Nielsen, Ph.D.DirectorAug 2021

Acquired (Jan 1, 2025). Acquired by Jabil Inc..